A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Cobimetinib|DRUG: Paclitaxel|DRUG: Placebo|DRUG: Atezolizumab|DRUG: Nab-Paclitaxel
Sponsor: Hoffmann-La Roche